Global Spinal Muscular Atrophy Medicine Market Insights, Research Forecast to 2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 128

Report ID: 4223

The global Spinal Muscular Atrophy Medicine market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Spinal Muscular Atrophy Medicine market based on company, product type, end user and key regions.

This report studies the global market size of Spinal Muscular Atrophy Medicine in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Spinal Muscular Atrophy Medicine in these regions.
This research report categorizes the global Spinal Muscular Atrophy Medicine market by top players/brands, region, type and end user. This report also studies the global Spinal Muscular Atrophy Medicine market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Astellas Pharma Inc.
AveXis, Inc.
Bioblast Pharma Ltd.
Cytokinetics, Inc. 24
F. Hoffmann-La Roche Ltd.
Genethon
Genzyme Corporation
GMP-Orphan SAS
Ionis Pharmaceuticals, Inc.
Longevity Biotech, Inc
Neurodyn Inc.
Neurotune AG
Novartis AG
Sarepta Therapeutics, Inc.
Voyager Therapeutics, Inc.
Vybion, Inc.
WAVE Life Sciences Ltd.

Market size by Product
LMI-070
ND-602
NT-1654
Nusinersen
NXD-30001
Others
Market size by End User
Hospital
Clinic
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Spinal Muscular Atrophy Medicine market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Spinal Muscular Atrophy Medicine market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Spinal Muscular Atrophy Medicine companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Spinal Muscular Atrophy Medicine submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Spinal Muscular Atrophy Medicine are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Spinal Muscular Atrophy Medicine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Study Coverage
1.1 Spinal Muscular Atrophy Medicine Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Spinal Muscular Atrophy Medicine Market Size Growth Rate by Product
1.4.2 LMI-070
1.4.3 ND-602
1.4.4 NT-1654
1.4.5 Nusinersen
1.4.6 NXD-30001
1.4.7 Others
1.5 Market by End User
1.5.1 Global Spinal Muscular Atrophy Medicine Market Size Growth Rate by End User
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Spinal Muscular Atrophy Medicine Market Size
2.1.1 Global Spinal Muscular Atrophy Medicine Revenue 2014-2025
2.1.2 Global Spinal Muscular Atrophy Medicine Sales 2014-2025
2.2 Spinal Muscular Atrophy Medicine Growth Rate by Regions
2.2.1 Global Spinal Muscular Atrophy Medicine Sales by Regions
2.2.2 Global Spinal Muscular Atrophy Medicine Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Spinal Muscular Atrophy Medicine Sales by Manufacturers
3.1.1 Spinal Muscular Atrophy Medicine Sales by Manufacturers
3.1.2 Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturers
3.1.3 Global Spinal Muscular Atrophy Medicine Market Concentration Ratio (CR5 and HHI)
3.2 Spinal Muscular Atrophy Medicine Revenue by Manufacturers
3.2.1 Spinal Muscular Atrophy Medicine Revenue by Manufacturers (2014-2019)
3.2.2 Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers (2014-2019)
3.3 Spinal Muscular Atrophy Medicine Price by Manufacturers
3.4 Spinal Muscular Atrophy Medicine Manufacturing Base Distribution, Product Types
3.4.1 Spinal Muscular Atrophy Medicine Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Spinal Muscular Atrophy Medicine Product Type
3.4.3 Date of International Manufacturers Enter into Spinal Muscular Atrophy Medicine Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global Spinal Muscular Atrophy Medicine Sales by Product
4.2 Global Spinal Muscular Atrophy Medicine Revenue by Product
4.3 Spinal Muscular Atrophy Medicine Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global Spinal Muscular Atrophy Medicine Breakdown Data by End User

6 North America
6.1 North America Spinal Muscular Atrophy Medicine by Countries
6.1.1 North America Spinal Muscular Atrophy Medicine Sales by Countries
6.1.2 North America Spinal Muscular Atrophy Medicine Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Spinal Muscular Atrophy Medicine by Product
6.3 North America Spinal Muscular Atrophy Medicine by End User

7 Europe
7.1 Europe Spinal Muscular Atrophy Medicine by Countries
7.1.1 Europe Spinal Muscular Atrophy Medicine Sales by Countries
7.1.2 Europe Spinal Muscular Atrophy Medicine Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Spinal Muscular Atrophy Medicine by Product
7.3 Europe Spinal Muscular Atrophy Medicine by End User

8 Asia Pacific
8.1 Asia Pacific Spinal Muscular Atrophy Medicine by Countries
8.1.1 Asia Pacific Spinal Muscular Atrophy Medicine Sales by Countries
8.1.2 Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Spinal Muscular Atrophy Medicine by Product
8.3 Asia Pacific Spinal Muscular Atrophy Medicine by End User

9 Central & South America
9.1 Central & South America Spinal Muscular Atrophy Medicine by Countries
9.1.1 Central & South America Spinal Muscular Atrophy Medicine Sales by Countries
9.1.2 Central & South America Spinal Muscular Atrophy Medicine Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Spinal Muscular Atrophy Medicine by Product
9.3 Central & South America Spinal Muscular Atrophy Medicine by End User

10 Middle East and Africa
10.1 Middle East and Africa Spinal Muscular Atrophy Medicine by Countries
10.1.1 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Countries
10.1.2 Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Spinal Muscular Atrophy Medicine by Product
10.3 Middle East and Africa Spinal Muscular Atrophy Medicine by End User

11 Company Profiles
11.1 Astellas Pharma Inc.
11.1.1 Astellas Pharma Inc. Company Details
11.1.2 Company Business Overview
11.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Products Offered
11.1.5 Astellas Pharma Inc. Recent Development
11.2 AveXis, Inc.
11.2.1 AveXis, Inc. Company Details
11.2.2 Company Business Overview
11.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2014-2019)
11.2.4 AveXis, Inc. Spinal Muscular Atrophy Medicine Products Offered
11.2.5 AveXis, Inc. Recent Development
11.3 Bioblast Pharma Ltd.
11.3.1 Bioblast Pharma Ltd. Company Details
11.3.2 Company Business Overview
11.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Products Offered
11.3.5 Bioblast Pharma Ltd. Recent Development
11.4 Cytokinetics, Inc. 24
11.4.1 Cytokinetics, Inc. 24 Company Details
11.4.2 Company Business Overview
11.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Products Offered
11.4.5 Cytokinetics, Inc. 24 Recent Development
11.5 F. Hoffmann-La Roche Ltd.
11.5.1 F. Hoffmann-La Roche Ltd. Company Details
11.5.2 Company Business Overview
11.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2014-2019)
11.5.4 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Products Offered
11.5.5 F. Hoffmann-La Roche Ltd. Recent Development
11.6 Genethon
11.6.1 Genethon Company Details
11.6.2 Company Business Overview
11.6.3 Genethon Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Genethon Spinal Muscular Atrophy Medicine Products Offered
11.6.5 Genethon Recent Development
11.7 Genzyme Corporation
11.7.1 Genzyme Corporation Company Details
11.7.2 Company Business Overview
11.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Genzyme Corporation Spinal Muscular Atrophy Medicine Products Offered
11.7.5 Genzyme Corporation Recent Development
11.8 GMP-Orphan SAS
11.8.1 GMP-Orphan SAS Company Details
11.8.2 Company Business Overview
11.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2014-2019)
11.8.4 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Products Offered
11.8.5 GMP-Orphan SAS Recent Development
11.9 Ionis Pharmaceuticals, Inc.
11.9.1 Ionis Pharmaceuticals, Inc. Company Details
11.9.2 Company Business Overview
11.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2014-2019)
11.9.4 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Products Offered
11.9.5 Ionis Pharmaceuticals, Inc. Recent Development
11.10 Longevity Biotech, Inc
11.10.1 Longevity Biotech, Inc Company Details
11.10.2 Company Business Overview
11.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Products Offered
11.10.5 Longevity Biotech, Inc Recent Development
11.11 Neurodyn Inc.
11.12 Neurotune AG
11.13 Novartis AG
11.14 Sarepta Therapeutics, Inc.
11.15 Voyager Therapeutics, Inc.
11.16 Vybion, Inc.
11.17 WAVE Life Sciences Ltd.

12 Future Forecast
12.1 Spinal Muscular Atrophy Medicine Market Forecast by Regions
12.1.1 Global Spinal Muscular Atrophy Medicine Sales Forecast by Regions 2019-2025
12.1.2 Global Spinal Muscular Atrophy Medicine Revenue Forecast by Regions 2019-2025
12.2 Spinal Muscular Atrophy Medicine Market Forecast by Product
12.2.1 Global Spinal Muscular Atrophy Medicine Sales Forecast by Product 2019-2025
12.2.2 Global Spinal Muscular Atrophy Medicine Revenue Forecast by Product 2019-2025
12.3 Spinal Muscular Atrophy Medicine Market Forecast by End User
12.4 North America Spinal Muscular Atrophy Medicine Forecast
12.5 Europe Spinal Muscular Atrophy Medicine Forecast
12.6 Asia Pacific Spinal Muscular Atrophy Medicine Forecast
12.7 Central & South America Spinal Muscular Atrophy Medicine Forecast
12.8 Middle East and Africa Spinal Muscular Atrophy Medicine Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Spinal Muscular Atrophy Medicine Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer